Pharmaceutical administration for severe hypertension during pregnancy: Network meta-analysis
Frontiers in Pharmacology · 09.01.2023 · 13
DOI: 10.3389/fphar.2022.1092501 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.01.2023. Verfasst von Nian-Jia Deng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Evidence-Based Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
To evaluate the efficacy of different pharmacologic treatment for severe hypertension during pregnancy.
Methods
Two reviewers searched Ovid MEDLINE, Ovid EMbase, and the Cochrane Library for randomized clinical trials from the establishment of the database to 15 July 2021 that were eligible for inclusion and analyzed the pharmaceuticals used for severe hypertension in pregnancy.
Results
29 relevant trials with 2,521 participants were involved. Compared with diazoxide in rate of achieving target blood pressure, other pharmaceuticals, including epoprostenol (RR:1.58, 95%CI:1.01–2.47), hydralazine\dihydralazine (RR:1.57, 95%CI:1.07–2.31), ketanserin (RR:1.67, 95%CI:1.09–2.55), labetalol (RR:1.54, 95%CI:1.04–2.28), nifedipine (RR:1.54, 95%CI:1.04–2.29), and urapidil (RR:1.57, 95%CI:1.00–2.47), were statistically significant in the rate of achieving target blood pressure. According to the SUCRA, diazoxide showed the best therapeutic effect, followed by nicardipine, nifedipine, labetalol, and nitroglycerine. The three pharmaceuticals with the worst therapeutic effect were ketanserin, hydralazine, and urapidil. It is worth noting that the high ranking of the top two pharmaceuticals, including diazoxide and nicardipine, comes from extremely low sample sizes. Other outcomes were reported in the main text.
Conclusion
This comprehensive network meta-analysis demonstrated that the nifedipine should be recommended as a strategy for blood pressure management in pregnant women with severe hypertension. Moreover, the conventional pharmaceuticals, including labetalol and hydralazine, showed limited efficacy. However, it was important to note that the instability of hydralazine reducing blood pressure and the high benefit of labetalol with high dosages intakes should also be of concern to clinicians.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Evidence-Based Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
- Department of Ultrasound, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zitieren
APA
Deng, N. J., Xian-Yu, C. Y., Han, R. Z., Huang, C. Y., Ma, Y. T., Li, H. J., Gao, T. Y., Liu, X., & Zhang, C. (2023). Pharmaceutical administration for severe hypertension during pregnancy: Network meta-analysis. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1092501
Vancouver
Deng NJ, Xian-Yu CY, Han RZ, Huang CY, Ma YT, Li HJ, et al. Pharmaceutical administration for severe hypertension during pregnancy: Network meta-analysis. Frontiers in Pharmacology. 2023;13. doi:10.3389/fphar.2022.1092501
BibTeX
@article{Deng2023,
author = {Deng, Nian-Jia and Xian-Yu, Chen-Yang and Han, Rui-Zheng and Huang, Cheng-Yang and Ma, Yu-Tong and Li, Hui-Jun and Gao, Teng-Yu and Liu, Xin and Zhang, Chao},
title = {Pharmaceutical administration for severe hypertension during pregnancy: Network meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {13},
doi = {10.3389/fphar.2022.1092501}
}
EUVIMED